CytRx abandons Phase II-stage tamibarotene for NSCLC
This article was originally published in Scrip
Executive Summary
CytRx is stopping development of tamibarotene after an independent Data Safety Monitoring Committee said it was unlikely to meet its primary endpoint in a Phase IIb trial as a first-line treatment for patients with advanced non-small-cell lung cancer.